Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

SOM 3 > pK > Flashcards

pK Flashcards

1
Q

what affects the rate and extent of absorption?

A

1.anatomical site
2.disease state
3.drug properties
4.formulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how are drugs absorbed ?

A

transcellular - thru the cell using carriers
paracellular - AQ environment between cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what does the rate of passive diffusion depend on?

A

-drug lipophilicity
-surface area available
-increase drug concentration
-thickness of epithelial layer
-potential mucus layer
-absorption area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what does the rate of carrier mediated depend on?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why are efflux transporters not good for absorption?

A

bring the drug back into the lumen, instead of being absorbed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what order of kinetics is used if the carrier transporter is saturated?

A

zero order

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how are drugs effluxed in the gut?

A

active transport
needs ATP to go against the drug conc. gradient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what drugs influence the effect of efflux receptors?

A

Substrates- can be taken out of the cell
Inhibitors- inhibit efflux transport, affcting bioavailability
Inducer- increase number of efflux transporters, increasing activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how are nanomedicines removed?

A

phagocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what happens in endocytosis?

A

The binding of a substrate to a receptor on cell wall, triggers formation of vesicles (endosome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how are drugs absorbed into the cell?

A

phagocytosis
pinocytosis
endocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is Pinocytosis

A

A process by which the cell takes in the fluids along with dissolved small molecules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

characteristics of subcutaneous injection

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

characteristics of intradermal injection

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

characteristics of intramuscular injection

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the drug properties that affect absorption?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is biopharmaceutical drug disposition system classification (BDDSC)?

A

class I - high solubility, high metabolism
class II - low solubility, high metabolism
class III - high solubility, poor metabolism
class IV - low solubility, poor metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are the formulation considerations of non-enteral routes? (Oro-mucosal, rectal, intranasal, pulmonary, transdermal)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what are some non-enteral routes?

A

Oro-mucosal, rectal, intranasal, pulmonary, transdermal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what does zero order absorption mean?

A

constant rate of absorption
independent of the dose
- carrier-mediated transport
- must have a high drug concentration
- modified release formulation
- must be a constant release rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what does first order absorption mean?

A

dependent on concentration
applies to MOST drugs
- rate is initially high
- rate decreases over time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

when may absorption be delayed?

A

using oral dosage forms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what factors can affect absorption?

A
  1. physiological factions
    e.g. delayed gastric emptying for oral dosage forms
  2. formulation factors
    - site specific delivery (e.g. colon)
    - dosage form
    - modified release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

how does bioavailability affect absorption?

A

Bioavailability is the fraction of the administered drug that reaches the systemic circulation in the unchanged form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what are some examples at each stage of first pass effect/pre-systemic circulation?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

what type of receptor do we ideally want on the apical or basal lateral side?

A

influx - apical side
efflux - basal lateral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

what are ATP-binding cassette (ABC’s)?

A

generally efflux transporters
which requires energy due to going against the concentration gradient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what are ATP-binding cassette examples?

A

P-glycoprotein (ABC1, Pgp)
multi-drug resistant associated protein (MRP, ABCC)
Breast cancer resistant protein (BCRP, ABCG2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

what are solute carrier transporter (SLC)?

A

generally influx transporters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

what are solute carrier transporter examples

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

what are the efflux/influx transporters name in the GIT?

A

efflux - ATP-binding cassette (ABC)
influx - solute carrier transporter (SLC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

which transporter (influx/efflux) in the GIT requires energy? and why?

A

efflux - ATP-binding cassette (ABC)

as they go against the concentration gradient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

when are proton dependent oligopeptide transporters used?

A

for the use of prodrug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

where are p-glycoprotein (ABC1, Pgp) expressed?

A

gut wall, BBB, kidney, liver, lung, colon

Pgp also found in the small intestine on the APICAL side of enterocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

what are some examples of Pgp inhibitors?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

what are some examples of Pgp inducers?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

what are some examples of Pgp substrates?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

what some enzymes that metabolise drugs in the small intestine?

A

CYP3A4
CYP2C9
UDP-glucuronosyltransferase
sulfotransferases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

which enzymes in the small intestine detoxicify the drug and how?

A

UDP-glucuronosyltransferase and sulfotransferases

by decreasing the lipophilicity and increasing the hydrophilicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

where is mainly CYP3A4 located?

A

gut, small percentage in the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

what enzyme is responsible for most drug metabolism?

A

CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

what are characteristics of CYP3A4?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

what are some examples of CYP2C9 drug metabolisers?

A

warfarin
phenytoin
losartan
diclofenac

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

how does UDP-glucuronosyltransferase drug metabolise?

A

conjugation of lipophilic drugs with glucuronic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

how does sulfotransferases drug metabolise?

A

sulfation of hydrophobic drug molecules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

what are the factors that affect rate of distribution?

A

tissue perfusion
membrane permeability
drug properties (plasma binding/tissue binding)
anatomical factors
tissue composition
physiological factors/barriers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

what are some examples of well/poor perfused tissue?

A

well perfused tissue -liver, kidney, lung

poorly perfused tissue -fatty tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

what are the extent of distribution?

A

MW
lipophilicity
ionisation - pH/pKa
protein binding
intracellular binding
patient factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

what factors means there’s an increase volume of distribution?

A

small MW
lipophilic
poorly perfused
unionised at a pH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

when does the equilibrium of drug distribution reach quickly? and how can this occur?

A

for tissues with high blood flow

occur by increasing the blood flow via exercise

51
Q

what is the apparent volume of distribution?

A

each body of compartment has a different volume

so we can use specific test compounds to estimate the volume of a given body compartment

52
Q

how can we estimate there total body water?

A

using ethanol

53
Q

how can we estimate the plasma?

A

using dextrans (large polysaccharides, polar molecules)

54
Q

whats the estimated values of apparent volume of distribution in each region? and their drug properties

A
55
Q

what type of drugs bind to albumin, alpha-1 acid glycoprotein, lipoproteins?

A

albumin=acidic drugs
alpha-1 acid glycoprotein= basic drugs
lipoproteins= neutral drugs

56
Q

true or false: protein-binding drugs can diffuse into tissue

A

false! must be unbound to cross as they are too large

57
Q

name some drugs that are affected by protein binding, lowering the volume distributed?

A
58
Q

how can molecular and physico-chemical properties affect protein binding?

A

due to the ability to interact with negatively charged membranes

59
Q

how can protein-related factors affect protein binding?

A

-change in protein concentration
e.g. liver disease, pregnancy, cystic fibrosis, aging, burns, malnutrition
-change in affinity for drugs

60
Q

how do drug interactions affect protein binding?

A

displacement of protein-bound drug by endogenous/exogenous compounds due to competition

61
Q

what happens if a drug prescribed bind to the same protein?

A

protein displacement risk

62
Q

risk of interaction of protein displacement occurs if…

A
  • highly bound to proteins (>90%)
  • small volume of distribution
  • interaction in initial stage of co-treatment
63
Q

what is the interaction between valproic acid and phenytoin?

A

valproic acid displaces phenytoin from protein binding sites, inhibiting metabolism of phenytoin

64
Q

what happens if the drug conc. is above the Css Max?

A

toxic

65
Q

what happens if the drug conc. is below the Css Min?

A

no drug effect due to below the MEC of the drug

66
Q

what does multiple administrations of a drug allow?

A

the conc. of the drug in the systemic circulation to be established - reach Css

drug administered= drug cleared
also known as INPUT = OUTPUT

67
Q

what factors depend on INPUT of multiple administrations?

A

DOSE
BIOAVAILABILITY
DOSING

68
Q

what factors depend on OUTPUT of multiple administrations?

A

Css
CLEARANCE

69
Q

what is the bioavailability of parenterals E.G. IV?

A

1

70
Q

how do you calculated INPUT of multiple administrations?

A
71
Q

how do you calculated OUTPUT of multiple administrations?

A
72
Q

if INPUT=OUTPUT, how can we calculate Css in multiple administration?

A
73
Q

drugs with a shorter half life will reach Css … in multiple IV bolus inj

A

Css FASTER

74
Q

how is maximum conc. at steady state calculated multiple IV bolus inj.?

A
75
Q

how is minimum conc. at steady state calculated in multiple IV bolus inj.?

A
76
Q

how is maximum conc. at steady state calculated in multiple administration?

A
77
Q

how is minimum conc. at steady state calculated in multiple administration?

A
78
Q

how is conc. at steady state at any time calculated in multiple administration?

A
79
Q

why do we monitor drug conc?

A

Can help identify common issues with dosing regimens:

  • Wrong drug
    - Plasma/blood concentration within therapeutic window/higher end
    * Different drug? Combination?
  • Wrong dose
    - Plasma/blood concentration at lower end of therapeutic window/below MEC
  • Adherence issues
  • Drug toxicity vs. disease progression
80
Q

what drugs are do we monitor? BROAD

A
  1. NTW drugs = high risk
  2. variable PK profiles for pts
  3. use in high risk patients e.g. polypharmacy affecting drug PK
81
Q

what drugs are do we monitor? SPECIFIC

A
  1. antibiotics - aminoglycosides, vancomycin
  2. anti-epileptics - phenytoin, carbamazepine, valproic acid
  3. CV drugs - digoxin
  4. immunosuppressants
  5. cytotoxic drugs - MTX
  6. Bronchodilators- theophylline
  7. lithium, tricyclic antidepressants
82
Q

when would you sample your pt for drug monitoring?

A

ALLOW Css to be established except if aminoglycoside/vancomycin treatments

If monitoring for efficacy- Css determined right before dosing

If monitoring for toxicity - sampling when highest concentration expected

If long elimination half-life or multiple-compartment PK - sample 6-8h after dosing

83
Q

what is measured when monitoring for drug conc.?

A

bound drug - to proteins/plasma
free drug is not routinely measures

84
Q

when is free drug used to monitor drug conc.?

A

when plasma/protein binding is affected due to …
1. Medical conditions (e.g. renal or hepatic disease, malnourishment, cystic fibrosis, etc.)
2. Drug interactions (e.g. displacement)

85
Q

how do you separate free and bound drug for drug monitoring?

A
  • equilibrium dialysis
  • ultracentrifuge
  • ultrafiltration
86
Q

when is metabolite drug conc monitored?

A

when the metabolite is pharmacologically active
contributes to adverse effects and toxicity

87
Q

how do you monitor metabolite drug conc.?

A

immunoassays
liquid chromatography

88
Q

how can drug-drug interactions impact absorption?

A

Impact on rate and/or extent of absorption
* Gastric emptying - e.g. Metoclopramide increase
* Dissolution rate / change in pH - e.g. Change in pH after PPI or antacids
* GIT motility - e.g. Opioids, Anti-cholinergic drugs
* Complexation - e.g. Cholestagel, calcium supplements
* Change in first-pass metabolism

89
Q

how can drug-drug interactions impact distribution?

A

Change in plasma/tissue protein binding
* Competition for the same binding site
* Drug with higher affinity/binding constant displaces the other
* Often both drugs are highly bound to proteins - Change to therapeutic response and/or toxicity

90
Q

how can drug-drug interactions impact metabolism?

A
  1. Inhibition of metabolising enzymes
    * Competitive inhibition
    * Non-competitive inhibition
    * Onset immediate…
    * Reversible
    * Irreversible
  2. induction of metabolising enzymes
    * Synthesis of new enzymes by the liver
    • Increased hepatic clearance
    • Reduce steady-state concentrations
      * Onset gradual
      * Recovery gradual
91
Q

how can drug-drug interactions impact absorption + excretion?

A

Impact on transporters (influx or efflux) - induction/inhibition

Intestine, brain, BBB, renal tubules, hepatocytes, placenta, etc.

  • Pgp =
  • Decreased intestinal absorption
  • Increase tubular/bile excretion
  • Decreased uptake in brain
92
Q

how can drug-drug interactions impact excretion?

A
  1. Renal excretion
    * Changes in pH of urine
    • Acidic drugs excreted faster at higher pH
    • Basic drugs excreted faster at acidic pH
      * Competition for active tubular secretion sites
    • Probenecid – inhibition of renal excretion
    • Aspirin and methotrexate
  2. Bile excretion
    * Hydrolysis by gut bacteria -> enterohepatic recycling ->longer drug effect
93
Q

when is herceptin used?

A

for the treatment of qHER2 expressed breast cancer

94
Q

what does polymorphism of CYP2D6 cause?

A
  1. complete deficiency - no expression of enzyme
  2. intermediate deficiency - some expression
  3. extensive deficiency - normal activity
  4. ultrarapid deficiency
95
Q

who is at risk of ultrarapid deficiency of CYP2D6?

A

middle eastern and north African people

96
Q

When are CYP2D6 used?

A

metabolism for elimination
metabolism for activation

97
Q

when does CYP2D6 activates a drug via metabolism?

A

codeine to morphine = faster drug onset

98
Q

when does CYP2D6 eliminate a drug via metabolism?

A

tricyclic antidepressants, antipsychotics = faster excretion

99
Q

how is codeine activated?

A

metabolised into morphine by CYP2D6 enzyme

100
Q

what is CYP2C9 responsible for?

A

metabolism of warfarin, phenytoin, losartan, glipizide, NSAIDs

101
Q

how is warfarin metabolised?

A

by CYP2C9 enzymes

102
Q

what is CYP2C19 responsible for?

A

Responsible for the metabolism of
* S-enantioners of diazepam, citalopram, propranolol, omeprazole
* Fluoxetine, sertraline, tricyclic antidepressants

103
Q

who is at risk of CYP2C19?

A

asia and south pacific are poor metabolisers

104
Q

what is Thiopurine methyltransferase (TPMT)?

A

Catalyses the S-methylation of thiopurine pro-drugs

105
Q

what is low activity of Thiopurine methyltransferase (TPMT) linked to?

A

higher risk of haematological ADRs

106
Q

what drugs are metabolised with Thiopurine methyltransferase (TPMT)?

A

azathioprine
mercaptopurine

107
Q

what is N-acetyltransferase (NAT)?

A

Catalyses the acetylation of different drugs to allow elimination

108
Q

what drugs are metabolised with N-acetyltransferase (NAT)?

A

isoniazid, hydralazine, phenelzine (MAOI)

109
Q

how does acetylation depend for isoniazid and hydralazine?

A
  1. For isoniazid (tuberculosis)
    * Slow acetylators = lower doses to avoid neurological ADRs
    * Fast acetylators = increased risk of hepatotoxicity (linked to metabolite concentration)
  2. For hydralazine (hypertension)
    * Slow acetylators = increased risk of SLE-like syndrome
110
Q

what is UDP-glucuronosyltransferase?

A

glucuronidation of different drugs

111
Q

when is UDP-glucuronosyltransferase used ?

A

irinotecan

112
Q

what makes patients poor metabolisers of irinotecan?

A

reduced UGT1A1 activity

113
Q

what is intra-patient variability?

A

variations of a drugs pharmacokinetic parameters, resulting in fairly different plasma concentration-time profiles after administration of the same dose to the same patient

114
Q

what is inter-patient variability?

A

variations of a drugs pharmacokinetic parameters, resulting in fairly different plasma concentration-time profiles after administration of the same dose to different patients

115
Q

what factors influence variability?

A
  • Genetic
  • Disease
  • Age and body size
  • Concomitant drugs - drug-drug interactions
  • Environmental factors (e.g. foods, pollutants)
  • Other factors include :
  • Adherence - correct dose and time
  • Pregnancy
  • Alcohol intake
  • Chronopharmacy - timing of drug administration
116
Q

how can circulatory system impact pK?

A

heart failure = diminished perfusion

117
Q

how can liver disease be effect pK?

A

Absorption
* Increase in bioavailability possible in cases of cirrhosis
* Reduced first-pass metabolism
* Physiological changes can also lead to drug bypassing portal circulation
* Potentially more problematic for drugs heavily metabolised by the liver

  1. Distribution
    * Decrease in protein levels (albumin, alpha-acid glycoprotein) for albumin-bound drugs
    * Displacement/competition
    • changes in Vd for albumin-bound drugs
    • Changes in Cl
  2. Metabolism and Excretion (bile)
    * Depending on importance of hepatic metabolism and clearance
    * CYP450 enzymes tend to be affected more and some enzymes affected more than others
118
Q

how can kidney disease be effect pK?

A

reduced clearance = increase half life
reduce protein binding
uremic toxins = reduce hepatic enzyme activity

119
Q

what are pK properties of anaesthetics?

A

highly lipid soluble = accumulate in fatty tissue

120
Q

what is the pharmacological considerations of administering anaesthetics?

A

obesity = higher proportion of adipose + lower water vol = affecting Vd of hydrophilic drugs

121
Q

what are the pK considerations of paediatric patients?

A

Absorption
* Infants after the newborn period have
* low stomach acid levels,
* delayed gastric emptying
* irregular intestinal peristalsis causing slower absorption of some drugs in infants and young children.

  • Distribution
  • Total body water as a fraction of body weight decreases throughout the first
    year of life.
  • However binding to plasma proteins is also reduced

Metabolism
* The various pathways of drug metabolism mature at different rates, and therefore the ability of the newborn to metabolise drugs differs both quantitatively and qualitatively from that of older subjects.
* After the enzyme system has mature (6 months), metabolism will depend on growth of the liver (perfusion, volume, bile function)

Excretion
* Glomerular filtration and renal tubule function in premature infants and newborns
is somewhat immature.
* GFR, normalized for body surface area, increases gradually reaching adult values at about 6 months

122
Q

what are the pK considerations of elderly patients?

A

Absorption
* There are a number of physiologic changes that potentially will alter drug absorption, GI motility, pH changes, etc. There has been little evidence, however, to suggest that this is of major consequence.

Distribution
* Great changes in body composition occur with age. Body fat increases from 15% to 30% and lean body weight decreases in proportion to total body weight. Thus the distribution of drugs that are sequestered into fatty tissues will be altered
* Changes to perfusion and cardia output can also impact distribution rates. Possible reduction in protein binding due to decreased albumin concentration
* Vd of lipophilic may be more affected

Metabolism
* The liver is the major organ involved in metabolism and liver blood
flow and liver mass tend to decrease with age.

Elimination
* With increasing age the glomerular filtration process is reduced by a reduction in kidney size (20%), reduction in the number of nephrons (35%), reduction in the number of functioning glomeruli (30%), and a decrease in renal blood flow (40- 50%). Adjustments should be made for drugs that are renally excreted.

123
Q

what are the pK considerations of pregnant patients?

A

Absorption
* Delayed gastric emptying, prolonged GI transit, reduced motility have been observed in pregnant patients and can cause reduced absorption rates. Elevated gastric pH can affect the absorption of some drugs. Nausea and vomiting can have an impact for orally administered drugs

Distribution
* Pregnancy is associated with increase blood flow, decreased levels of albumin and alpha-acid glycoprotein will affect protein binding. Increased levels of unbound drug can affect response and increase risk of ADRs. Increase in body weight linked to increase extracellular and intravascular volumes, which can affect distribution of hydrophilic drugs, while increase in body fat can change Vd of lipophilic drugs.

Metabolism
*Both oestrogen and progesterone and induce and inhibit CYP metabolising enzymes. Increase in blood flow can lead to lower plasma concentration of drugs with high extraction ratio which will be metabolised more extensively

Elimination
*Renal blood flow increases in pregnancy which increased renal excretion of hydrophilic drugs. For drugs that are eliminated by the kidney after metabolism, adjustment needs to consider impact of pregnancy on both metabolic and renal clearance

124
Q

what are the pK considerations of lactating patients?

A

Small vs. plasma concentration for nursing patients but can represent a high dose for infants
* Drug properties: pH slightly more acidic in breast tissue (7.1) so some basic drugs may become ionised and unable to transfer back to plasma. Drugs transported by passive diffusion, so lipophilic drug may accumulate more. Macromolecules less likely to be excreted in milk. Protein binding will have an impact.
* Pharmacology: concentration gradient plasma:milk, dose, route, frequency and time of feeding will all affect how much of the drugs is excreted in milk.
* Infant: dose will depends of volume of milk and drug concentration in nursing patient. Low accumulation, but immaturity of metabolism and excretion could be problematic.

SOM 3 (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions